Efficacy and pharmacodynamic responses
TG, hepatic steatosis, SAD
HEPATIC STEATOSIS
Results across multiple cohorts suggested robust, consistent and durable pharmacodynamic effects through at least 12 weeks, after single (day 1) or repeat (days 1 and 29) doses of ARO-ANG3 in HPs and repeat (days 1 and 29) doses for hepatic steatosis cohorts. Therefore, results summarized in the following sections report key pharmacodynamic and lipid data (ANGPTL3, TG, non-HDL-C, VLDL-C, LDL-C, HDL-C and ApoB concentrations) 12 weeks after the last dose, corresponding to day 85 for single dose (HP SAD cohorts) and day 113 for multiple doses (HP MAD and hepatic steatosis cohorts). Results from these analyses can be found in Table Pharmacodynamic effects of ARO-ANG3 on serum ANGPTL3 and lipid-related variablesNS, not significant.Note: Friedewald calculation was used for LDL-C measurements, unless TGs were >400 mg dl**